Back to top

Analyst Blog

In light of the offers and interests received so far, Elan Corporation, plc recently announced that it is gearing up for a formal sale process. Elan share prices shot up significantly following the announcement.

Elan also advised its shareholders not to tender Royalty Pharma’s latest offer of $13.00 per share in cash, along with a contingent value right (CVR) of up to $2.50 per share. However, Elan stated in its press release that it will invite Royalty Pharma to participate in the sale process.

We remind investors that not so long ago the Board of Directors of Elan rejected Royalty Pharma’s latest offer to acquire all its shares stating that the offer of $13 plus an up to $2.50 CVR substantially undervalued the company. The previous three offers of $12.50 per share, $11.25 per share and $11.00 per share were duly rejected.

Meanwhile, Elan’s shareholders rejected the majority of the company’s proposed strategic transactions at the Extraordinary General Meeting (EGM). The shareholders turned down the proposed acquisition of AOP Orphan Pharmaceuticals and the Theravance Inc. (THRX - Analyst Report) transaction. Moreover, the proposed divestment of the company’s pipeline candidate ELND005 (agitation/aggression in Alzheimer’s disease and Downs Syndrome) was also rejected.

However, the shareholders approved the company’s proposed $200 million share repurchase program.

We remind investors that in Apr 2013 Elan sold its Tysabri stake to Biogen Idec Inc. (BIIB - Analyst Report). Elan currently receives royalty payments at 12% on worldwide net sales of the multiple sclerosis drug. After the first year, Elan is expected to receive a royalty of 18% on up to $2 billion of global net sales of Tysabri and 25% thereafter on over $2 billion of global net sales of Tysabri.

Elan presently carries a Zacks Rank #2 (Buy). However, Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) currently looks better positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%